natgillin/translations-raw huggingface dataset:
In PEGASUS, dyspnoea was reported in 14.2% of patients taking ticagrelor 60 mg twice daily and in 5.5% of patients taking ASA alone. 
U studiji PEGASUS, dispneja je prijavljena u 14,2% bolesnika koji su uzimali tikagrelor od 60 mg dvaput dnevno i u 5,5% bolesnika koji su uzimali samo acetilsalicilatnu kiselinu.
Brilique affects cells called ‘platelets' (also called thrombocytes). 
Brilique djeluje na stanice koje se nazivaju krvnim pločicama (ili trombocitima).
No increased bleeding risk was seen for fatal bleeding and only a minor increase was observed in intracranial haemorrhages, as compared to ASA therapy alone. 
Nije zamijećen povećan rizik od fatalnih krvarenja, dok je za intrakranijalna krvarenja zamijećeno samo malo povećanje, u usporedbi s terapijom samo acetilsalicilatnom kiselinom.
Patients were ineligible if there was planned use of a P2Y12 receptor antagonist, dipyridamole, cilostazol, or anticoagulant therapy during the study period; if they had a bleeding disorder or a history of an ischaemic stroke or intracranial bleeding, a central nervous system tumour or an intracranial vascular abnormality; if they had had gastrointestinal bleeding within the previous 6 months or major surgery within the previous 30 days. 
Bolesnici nisu bili pogodni za sudjelovanje ako je postojala planirana primjena antagonista P2Y12 receptora, dipiridamola, cilostazola ili antikoagulantne terapije tijekom razdoblja ispitivanja; ako su imali poremećaj krvarenja ili povijest ishemijskog moždanog udara ili intrakranijalnog krvarenja, tumor središnjeg živčanog sustava ili abnormalnost intrakranijalnih krvnih žila; ako su imali krvarenje u probavnom sustavu unutar prethodnih 6 mjeseci ili veliki kirurški zahvat unutar prethodnih 30 dana.
What Brilique contains • The active substance is ticagrelor. 
Što Brilique sadrži • Djelatna tvar je tikagrelor.
Characteristic 
Karakteristika
Co-administration of ticagrelor with heparin, enoxaparin or desmopressin had no effect on activated partial thromboplastin time (aPTT), activated coagulation time (ACT) or factor Xa assays. 
Istodobna primjena tikagrelora s heparinom, enoksaparinom ili dezmopresinom nije imala učinka na pretrage: aktivirano parcijalno tromboplastinsko vrijeme (APTV), aktivirano vrijeme zgrušavanja (activated coagulation time - ACT) ili faktor zgrušavanja Xa.
Ingestion of a high-fat meal resulted in a 21% increase in ticagrelor AUC and 22% decrease in the active metabolite Cmax but had no effect on ticagrelor Cmax or the AUC of the active metabolite. 
Unos obroka s visokim udjelom masti je rezultirao povećanjem AUC-a tikagrelora za 21% i smanjenjem Cmax aktivnog metabolita za 22%, ali nije imao nikakav učinak na Cmax tikagrelora ili AUC aktivnog metabolita.
Other concomitant therapy 
Druge istodobne terapije
Co-administration of ticagrelor with doses of simvastatin exceeding 40 mg daily could cause adverse reactions of simvastatin and should be weighed against potential benefits. 
Istodobna primjena tikagrelora s dozama simvastatina koje prelaze 40 mg dnevno može uzrokovati nuspojave uzrokovane simvastatinom, što treba odvagati u odnosu na potencijalne prednosti.
Medicinal products known to induce bradycardia 
Lijekovi za koje je poznato da potiču bradikardiju
In patients who have developed HIT, the benefit-risk of continued treatment with ticagrelor should be assessed, taking both the prothrombotic state of HIT and the increased risk of bleeding with concomitant anticoagulant and ticagrelor treatment into consideration. 
Kod bolesnika u kojih se razvije HIT potrebno je ocijeniti omjer koristi i rizika nastavka liječenja tikagrelorom, uzimajući u obzir i protrombotsko stanje kod HIT-a i povećan rizik od krvarenja kod istodobnog liječenja antikoagulansima i tikagrelorom.
Ticagrelor orodispersible tablets, dispersed in saliva and swallowed without water or suspended in water and administered through a nasogastric tube into the stomach, were bioequivalent to film-coated whole tablets (AUC and Cmax within 80-125% for ticagrelor and the active metabolite). 
Tikagrelor raspadljive tablete za usta, otopljene u slini i progutane bez vode ili otopljene u vodi i primijenjene kroz nazogastričnu cijev u želudac, bile su bioekvivalentne cjelovitim filmom obloženim tabletama (AUC i Cmax unutar 80-125% za tikagrelor i aktivni metabolit).
Treating 54 ACS patients with ticagrelor instead of clopidogrel will prevent 1 atherothrombotic event; treating 91 will prevent 1 CV death (see Figure 1 and Table 4). 
Liječenje 54 bolesnika s akutnim koronarnim sindromom tikagrelorom umjesto klopidogrelom spriječit će 1 aterotrombotični događaj; liječenje 91 bolesnika spriječit će 1 KV smrt (pogledajte sliku 1 i tablicu 4).
Exposure to ticagrelor was approximately 20% lower and exposure to the active metabolite was approximately 17% higher in patients with severe renal impairment (creatinine clearance <30 ml/min) compared to subjects with normal renal function. 
Izloženost tikagreloru bila je približno 20% manja, a izloženost aktivnom metabolitu približno 17% veća kod bolesnika s teškim oštećenjem funkcije bubrega (klirens kreatinina < 30 ml/min) u usporedbi s osobama s normalnom bubrežnom funkcijom.
Patients can be switched from clopidogrel to ticagrelor without any interruption of antiplatelet effect (see section 4.2). 
Bolesnici se mogu prebaciti s klopidogrela na tikagelor bez ikakvog prekidanja antitrombocitnog učinka (vidjeti dio 4.2).
• The PEGASUS TIMI-54 [PrEvention with TicaGrelor of SecondAry Thrombotic Events in High-RiSk AcUte Coronary Syndrome Patients] study, a comparison of ticagrelor combined with ASA to ASA therapy alone. 
• Studija PEGASUS TIMI-54 [PrEvention with TicaGrelor of SecondAry Thrombotic Events in High-RiSk AcUte Coronary Syndrome Patients], usporedba kombinacije tikagrelora i acetilsalicilatne kiseline sa samostalnom terapijom acetilsalicilatnom kiselinom.
• quinidine and diltiazem (used to treat abnormal heart rhythms) 
• kinidin i diltiazem (za liječenje poremećaja srčanog ritma),
Cmax and AUC for ticagrelor were 12% and 23% higher in patients with mild hepatic impairment compared to matched healthy subjects, respectively, however, the IPA effect of ticagrelor was similar between the two groups. 
Cmax i AUC za tikagrelor bili su 12% i 23% viši u bolesnika s blagim oštećenjem funkcije jetre u usporedbi sa odgovarajućim zdravim ispitanicima, međutim IPA učinak tikagrelora bio je sličan između dvije skupine.
• The PLATO [PLATelet Inhibition and Patient Outcomes] study, a comparison of ticagrelor to clopidogrel, both given in combination with ASA and other standard therapy. 
• Studija PLATO [PLATelet Inhibition and Patient Outcomes], usporedba tikagrelora i klopidogrela, oba primijenjena u kombinaciji s acetilsalicilatnom kiselinom i drugom standardnom terapijom.
In patients with stable coronary artery disease (CAD) on ASA, ticagrelor demonstrates a rapid onset of pharmacological effect as demonstrated by a mean inhibition of platelet aggregation (IPA) for ticagrelor at 0.5 hours after 180 mg loading dose of about 41%, with the maximum IPA effect of 89% by 2-4 hours post dose, and maintained between 2-8 hours. 
U bolesnika sa stabilnom bolesti koronarnih arterija na acetilsalicilatnoj kiselini, tikagrelor pokazuje brz nastup farmakološkog učinka kako je pokazano srednjom vrijednošću inhibicije agregacije trombocita (Inhibition of Platelet Aggregation - IPA) od oko 41% za tikagrelor 0,5 sati nakon 180 mg udarne doze, s maksimalnim IPA učinkom od 89% za 2 - 4 sata nakon uzimanja doze, koji je održan između 2 - 8 sati.
Patients with asthma/chronic obstructive pulmonary disease (COPD) may have an increased absolute risk of experiencing dyspnoea with ticagrelor. 
Bolesnici s astmom/kroničnom opstruktivnom plućnom bolesti (KOPB-om) mogu imati povećani apsolutni rizik od dispneje tijekom liječenja tikagrelorom.
There were 6 fatal ICHs with ticagrelor 60 mg and 5 fatal ICHs with ASA therapy alone. 
Bilo je 6 fatalnih intrakranijalnih krvarenja s tikagrelorom od 60 mg i 5 fatalnih intrakranijalnih krvarenja s terapijom samo acetilsalicilatnom kiselinom.
There were few fatal bleeding events in the study, 11 (0.3%) for ticagrelor 60 mg and 12 (0.3%) for ASA therapy alone. 
Bilo je nekoliko fatalnih događaja krvarenja tijekom studije, 11 (0,3%) za tikagrelor od 60 mg i 12 (0,3%) za terapiju samo acetilsalicilatnom kiselinom.
How Brilique works 
Kako Brilique djeluje
Brilique contains an active substance called ticagrelor. 
Brilique sadrži djelatnu tvar koja se naziva tikagrelor.
Patients of Asian descent have a 39% higher mean bioavailability compared to Caucasian patients. 
Bolesnici azijskog podrijetla imaju 39% veću srednju bioraspoloživost u odnosu na bolesnike bijele rase.
Other CYP3A inducers (e.g. phenytoin, carbamazepine and phenobarbital) would be expected to decrease the exposure to ticagrelor as well. 
Očekuje se da bi drugi induktori CYP3A (npr. fenitoin, karbamazepin i fenobarbital) također smanjili izloženost tikagreloru.
• Simvastatin - Co-administration of ticagrelor with simvastatin increased simvastatin Cmax by 81% and AUC by 56% and increased simvastatin acid Cmax by 64% and AUC by 52% with some individual increases equal to 2- to 3-fold. 
• Simvastatin - istodobna primjena tikagrelora sa simvastatinom je povećala Cmax simvastatina za 81% i AUC simvastatina za 56%, i povećala je Cmax simvastatinske kiseline za 64% i AUC simvastatinske kiseline za 52% s nekim pojedinačnim povećanjima od 2 do 3 puta.
Co-administration of ticagrelor with tolbutamide resulted in no change in the plasma levels of either medicinal product, which suggests that ticagrelor is not a CYP2C9 inhibitor and unlikely to alter the CYP2C9 mediated metabolism of medicinal products like warfarin and tolbutamide. 
Istodobna primjena tikagrelora s tolbutamidom je rezultirala u nepromijenjenim plazmatskim razinama oba lijeka, što upućuje na to da tikagrelor nije inhibitor CYP2C9 te da je malo vjerojatno da mijenja metabolizam lijekova posredovan CYP2C9 kao npr. za varfarin ili tolbutamid.
Continue taking Brilique as long as your doctor tells you. 
Nastavite uzimati lijek Brilique toliko dugo koliko Vam je propisao liječnik.
How to take Brilique 
Kako uzimati Brilique
clarithromycin, nefazodone, ritonavir and atazanavir), as co-administration may lead to a substantial increase in exposure to ticagrelor (see section 4.5). 
klaritromicin, nefazodon, ritonavir i atazanavir), budući da istodobna primjena može dovesti do značajnog povećanja izloženosti tikagreloru (vidjeti dio 4.5).
• History of intracranial haemorrhage (see section 4.8). 
• Intrakranijalno krvarenje u anamnezi (vidjeti dio 4.8).
In patients that had moderate or severe elevation in one or more liver function tests at baseline, ticagrelor plasma concentrations were on average similar or slightly higher as compared to those without baseline elevations. 
U bolesnika koji su na početku studije imali umjereno ili teško povišenje za jednu ili više pretraga jetrene funkcije, koncentracije tikagrelora u plazmi bile su u prosjeku slične ili više od onih u bolesnika bez početnog povišenja.
There are no or limited amount of data from the use of ticagrelor in pregnant women. 
Nema podataka ili su podaci o primjeni tikagrelora u trudnica ograničeni.
PLATO Total Major PLATO Major Fatal/Life-Threatening Non-CABG PLATO Major Non-Procedural PLATO Major PLATO Total Major + Minor Non-Procedural PLATO Major + Minor TIMI-defined Major TIMI-defined Major + Minor 
PLATO ukupno velika PLATO velika fatalna / opasna po život Ne-CABG PLATO velika Ne-proceduralna PLATO velika PLATO ukupna velika + manja Ne-proceduralna PLATO velika + manja Definirana po TIMI kao velika Definirana po TIMI kao velika + manja
There were more intracranial non-procedural bleeds with ticagrelor (n=27 bleeds in 26 patients, 0.3%) than with clopidogrel (n=14 bleeds, 0.2%), of which 11 bleeds with ticagrelor and 1 with clopidogrel were fatal. 
Zabilježeno je više neproceduralnih intrakranijalnih krvarenja s tikagrelorom (n=27 krvarenja u 26 ispitanika, 0,3%) u odnosu na klopidogrel (n=14 krvarenja, 0,2%) od čega je 11 krvarenja s tikagrelorom i jedno s klopidogrelom bilo fatalno.
Few patients in PLATO had fatal bleeds: 20 (0.2%) for ticagrelor and 23 (0.3%) for clopidogrel (see section 4.4). 
Nekoliko bolesnika u PLATO studiji je imalo fatalna krvarenja: 20 (0,2%) s tikagrelorom i 23 (0,3%) s klopidogrelom (vidjeti dio 4.4).
Uric acid elevations: In PLATO, serum uric acid increased to more than upper limit of normal in 22% of patients receiving ticagrelor compared to 13% of patients receiving clopidogrel. 
Povišenje razine uratne kiseline: u studiji PLATO, serumska razina uratne kiseline povećana je iznad normalne gornje granice u 22% bolesnika koji su primali tikagrelor u odnosu na 13% bolesnika koji su primali klopidogrel.
The bleeding profile of ticagrelor 60 mg was consistent across multiple pre-defined subgroups (e.g. by age, gender, weight, race, geographic region, concurrent conditions, concomitant therapy and medical history) for TIMI Major, TIMI Major or Minor and PLATO Major bleeding events. 
Profil krvarenja za tikagrelor od 60 mg bio je dosljedan u višestrukim prethodno definiranim podskupinama (npr. po dobi, spolu, tjelesnoj težini, rasi, geografskoj regiji, istodobno prisutnim stanjima, istodobno primjenjivanim lijekovima i anamnezi) za događaje krvarenja u kategorijama TIMI velika, TIMI velika ili manja te PLATO velika.
Lapses in therapy should also be avoided. 
Trebalo bi također izbjegavati propuštanje uzimanja terapije.
Non-CABG PLATO Major bleeding was increased with ticagrelor compared clopidogrel in patients with one or more CYP2C19 loss of function alleles, but similar to clopidogrel in patients with no loss of function allele. 
Ne-CABG veliko PLATO krvarenje je bilo povećano s tikagrelorom u usporedbi s klopidogrelom kod bolesnika koji imaju gubitak jednog ili više funkcionalnih alela CYP2C19, ali je slično klopidogrelu kod bolesnika bez gubitka funkcionalnih alela.
Clinical pharmacology interaction studies showed that co-administration of ticagrelor with heparin, enoxaparin and ASA or desmopressin did not have any effect on the pharmacokinetics of ticagrelor or the active metabolite or on ADP-induced platelet aggregation compared with ticagrelor alone. 
Kliničke farmakološke studije interakcija su pokazale da istodobna primjena tikagrelora s heparinom, enoksaparinom i acetilsalicilatnom kiselinom ili dezmopresinom nije imala nikakav učinak na farmakokinetiku tikagrelora ili aktivnog metabolita, kao ni na ADP-induciranu agregaciju trombocita, u usporedbi sa samim tikagrelorom.
The major metabolite of ticagrelor is AR-C124910XX, which is also active as assessed by in vitro binding to the platelet P2Y12 ADP-receptor. 
Glavni metabolit tikagrelora je AR-C124910XX, koji je također aktivan kada se procjenjuje in vitro vezanjem za P2Y12 ADP-receptor trombocita.
Ticagrelor as well as the active metabolite are P-gp substrates. 
Tikagrelor, kao i aktivni metabolit, je supstrat P-glikoproteina.
The most commonly reported adverse reactions in patients treated with ticagrelor were bleeding and dyspnoea (see section 4.4). 
Najčešće prijavljivane nuspojave u bolesnika liječenih tikagrelorom bile su krvarenje i dispneja (vidjeti dio 4.4).
Ticagrelor should be used with caution in patients with history of asthma and/or COPD. 
Tikagrelor treba koristiti s oprezom kod bolesnika koji imaju u anamnezi astmu i/ili KOPB.
Dose adjustment is not recommended, but ticagrelor should be used with caution (see sections 4.4 and 5.2). 
Prilagodba doze se ne preporučuje, ali tikagrelor se treba primjenjivati s oprezom (vidjeti dijelove 4.4 i 5.2).
No data are available on concomitant use of ticagrelor with other active substances that also are potent P-gp inhibitors and moderate CYP3A4 inhibitors (e.g. verapamil, quinidine) that also may increase ticagrelor exposure. 
Nema dostupnih podataka o istodobnoj primjeni tikagrelora s drugim djelatnim tvarima koje su također potentni inhibitori P-gp-a i umjereni inhibitori CYP3A4 (npr. verapamil i kinidin) koji također mogu povećati izloženost tikagreloru.
TIMI Major or Minor 
TIMI velika ili manja
Hazard ratio and p-values are calculated separately for ticagrelor vs. ASA therapy alone from Cox proportional hazards model with treatment group as the only explanatory variable. 
Omjeri hazarda i p-vrijednosti su izračunate odvojeno za tikagrelor naprema terapiji samo acetilsalicilatnom kiselinom iz Coxovog modela proporcionalnih hazarda s terapijskom skupinom kao jedinom eksplanatornom varijablom.
The increase in Holter-detected ventricular pauses with ticagrelor was higher in patients with chronic heart failure (CHF) than in the overall study population during the acute phase of ACS, but not at one month with ticagrelor or compared to clopidogrel. 
Povećanje ventrikularnih pauza detektiranih Holterom za vrijeme primjene tikagrelora je bilo veće kod bolesnika sa kroničnim zatajivanjem srca (KZS) nego u ukupnoj populaciji studije za vrijeme akutne faze akutnih koronarnih sindroma, ali ne nakon mjesec dana primjene tikagrelora ili u usporedbi s klopidogrelom.
P-gp substrates (including digoxin, cyclosporine) Concomitant administration of ticagrelor increased the digoxin Cmax by 75% and AUC by 28%. 
Supstrati P-gp-a (uključujući digoksin, ciklosporin) Istodobna primjena tikagrelora povećala je Cmax digoksina za 75% i AUC digoksina za 28%.
There was no effect of ticagrelor on cyclosporine blood levels. 
Nije bilo učinka tikagrelora na razine ciklosporina u krvi.
Dyspnoea, a sensation of breathlessness, is reported by patients treated with ticagrelor. 
Dispneju, osjećaj nedostatka zraka, su prijavili bolesnici liječeni s tikagrelorom.
Platelet transfusion is unlikely to be of clinical benefit in patients with bleeding (see section 4.4). 
Malo je vjerojatno da će transfuzija trombocita biti od kliničke koristi u bolesnika sa krvarenjem (vidjeti dio 4.4).
PEGASUS study (History of Myocardial Infarction) 
Studija PEGASUS (infarkta miokarda u anamnezi)
Ticagrelor has not been studied in patients with severe hepatic impairment and there is no pharmacokinetic information in patients with moderate hepatic impairment. 
Tikagrelor nije proučavan u bolesnika s teškim oštećenjem funkcije jetre te ne postoje podaci o farmakokinetici u bolesnika s umjerenim oštećenjem funkcije jetre.
However, due to potential pharmacodynamic interactions, caution should be exercised with the concomitant administration of ticagrelor with medicinal products known to alter haemostasis. 
Ipak, zbog mogućih farmakodinamskih interakcija potreban je oprez pri istodobnoj primjeni tikagrelora s lijekovima za koje se zna da mijenjaju hemostazu.
The rate of discontinuations with ticagrelor 60 mg due to bleeding and dyspnoea was higher in patients >75 years (42%) than in younger patients (range: 23-31%), with a difference versus placebo higher than 10% (42% vs. 29%) in patients >75 years. 
Stopa prekida liječenja tikagrelorom u dozi od 60 mg zbog krvarenja i dispneje bila je viša u bolesnika u dobi od >75 godina (42%) nego u mlađih bolesnika (raspon: 23 - 31%), uz razliku naprema placebu višu od 10% (42% naprema 29%) u bolesnika starijih od 75 godina.
A weakly significant treatment interaction was observed with region whereby the hazard ratio (HR) for the primary endpoint favours ticagrelor in the rest of world but favours clopidogrel in North America, which represented approximately 10% of the overall population studied (interaction p-value=0.045). 
Hazard Ratio - HR) za primarnu mjeru ishoda studije ide u korist tikagrelora u cijelom svijetu, osim u Sjevernoj Americi, koja je predstavljala približno 10% ukupne populacije u studiji, gdje ide u korist klopidogrela (p-vrijednost interakcije = 0,045).
If you stop taking Brilique, it may increase your chances of having another heart attack or stroke or dying from a disease related to your heart or blood vessels. 
Ukoliko prestanete uzimati Brilique, to može povećati vjerojatnost za još jedan srčani ili moždani udar ili rizik od smrti zbog bolesti povezanih s Vašim srcem i krvnim žilama.
ASA alone N = 7067 
N = 7067
Intracranial bleeding: 
Intrakranijalno krvarenje:
The observed increased risk of TIMI Major bleeding with ticagrelor 60 mg was primarily due to a higher frequency of Other TIMI Major bleedings driven by events in the gastrointestinal SOC. 
Opažen povećani rizik od TIMI velikih krvarenja s tikagrelorom od 60 mg bio je primarno posljedica veće učestalosti Drugih TIMI velikih krvarenja, potaknutih događajima u probavnom organskom sustavu.
Exploratory analyses suggest a possible association with ASA dose such that reduced efficacy was observed with ticagrelor with increasing ASA doses. 
Istraživačke analize ukazuju na moguću povezanost s dozama acetilsalicilatne kiseline na način da je primijećena smanjena djelotvornost tikagrelora sa povećanjem doze acetilsalicilatne kiseline.
During the Holter substudy in PLATO, more patients had ventricular pauses >3 seconds with ticagrelor than with clopidogrel during the acute phase of their ACS. 
U podstudiji Holter studije PLATO, više je bolesnika imalo ventrikularne pauze > 3 sekunde s tikagrelorom nego s klopidogrelom za vrijeme akutne faze njihovih akutnih koronarnih sindroma.
Compared with clopidogrel, patients with asthma/COPD treated with ticagrelor may have an increased risk of experiencing non-serious dyspnoea (3.29% ticagrelor versus 0.53% clopidogrel) and serious dyspnoea (0.38% ticagrelor versus 0.00% clopidogrel). 
U usporedbi s klopidogrelom, bolesnici s astmom/KOPB-om liječeni tikagrelorom mogu imati povećani rizik od pojave dispneje koja nije ozbiljna (3,29% tikagrelor u odnosu na 0,53% klopidogrel) i ozbiljne dispneje (0,38% tikagrelor u odnosu na 0,00% s klopidogrelom).
Mon Tue Wed Thu Fri Sat Sun Sun/Moon symbol 
Pon Uto Sri Čet Pet Sub Ned simbol sunca i mjeseca
PLATO genetic substudy 
Genetičko podispitivanje PLATO
Ticagrelor and clopidogrel did not differ in rates of PLATO Major Fatal/Life-threatening bleeding, PLATO total Major bleeding, TIMI Major bleeding, or TIMI Minor bleeding (Table 2). 
Tikagrelor i klopidogrel se nisu razlikovali u pogledu učestalosti krvarenja za PLATO velika fatalna/krvarenja opasna po život, PLATO ukupna velika krvarenja, TIMI velika krvarenja, ili TIMI manja krvarenja (tablica 2).
In clinical studies, ticagrelor was commonly administered with ASA, proton pump inhibitors, statins, beta-blockers, angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers as needed for concomitant conditions for long-term and also heparin, low molecular weight heparin and intravenous GpIIb/IIIa inhibitors for short durations (see section 5.1). 
U kliničkim studijama, tikagrelor se obično primjenjivao s acetilsalicilatnom kiselinom, inhibitorima protonske pumpe, statinima, beta-blokatorima, inhibitorima angiotenzin konvertirajućeg enzima (ACE) i blokatorima angiotenzinskih receptora koji su se primjenjivali dugoročno po potrebi za pridružena medicinska stanja, kao i s heparinom, heparinom niske molekularne težine i intravenskim inhibitorima GpIIb/IIIa koji su se primjenjivali kratkoročno (vidjeti dio 5.1).
The superiority of ticagrelor over clopidogrel in reducing major CV events was not significantly affected by patient CYP2C19 or ABCB1 genotype. 
Na superiornost tikagrelora nad klopidogrelom u smanjenju velikih KV događaja genotip CYP2C19 i ABCB1 bolesnika nije značajno utjecao.
Creatinine elevations 
Povišene razine kreatinina
How to take Brilique Do not open the blister until it is time to take your medicine. 
Nemojte otvarati blister do trenutka kada je potrebno uzeti lijek.
Clopidogrel N=9186 p-value* 
N=9186 p-vrijednost*
Ticagrelor should be used with caution in patients with history of asthma and/or COPD (see section 4.4). 
Tikagrelor treba koristiti s oprezom kod bolesnika koji imaju u anamnezi astmu i/ili KOPB (vidjeti dio 4.4).
If the association cannot be avoided, their concomitant use should be made with caution. 
Ako se kombinacija ovih lijekova ne može izbjeći, potreban je oprez prilikom njihove istodobne primjene.
The following side effects may happen with this medicine: 
Pri uzimanju ovog lijeka moguće su sljedeće nuspojave: